Myelodysplastic Syndromes – Epidemiology – Extrapolated Worldwide Coverage
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key MDS patient populations, covering 171 countries and more than 99% of the global population, delivered in an interactive dashboard-style download.
Use the Extrapolated Worldwide Coverage dashboard to do the following:
- View 10-year forecasts of the first-line drug-treatable population and diagnosed incident cases for all 171 countries, stratified by region and World Bank income status.
- Aggregate country-level estimates into region-level estimates, according to user preference or as required by regulators for orphan drug designations.
- Visualize global correlations between disease risk or size of patient population and key indicators of market opportunity such as GDP per capita and healthcare spend per capita.
- Generate and export global heat maps of disease risk or size of patient population.
The Extrapolated Worldwide Coverage dashboard is available as an Excel file in the Downloads section at the top right of this page. It is available for purchase by clients with subscriptions to all 45 countries covered by Clarivate Epidemiology. For subscription and entitlement queries, please contact Clarivate.support@clarivate.com.
Related Market Assessment Reports
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
Report
Paroxysmal Nocturnal Hemoglobinuria – Unmet Need – Unmet Need – Paroxysomal Nocturnal Hemoglobinuria (US/EU)
The treatment landscape for paroxysmal nocturnal hemoglobinuria (PNH) has shifted dramatically in the past decade, moving beyond supportive care to transformative complement inhibition therapies…
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Landscape & Forecast – Disease Landscape & Forecast (G7)
The non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) therapy market is rapidly evolving as novel agents provide alternatives to conventional chemoimmunotherapy regimens. This…
